CD274 and neoplasm: These are PD-1 and PDL-1 (Programmed cell death—protein and ligand 1) inhibitors, because cancer cells, in order to avoid recognition and destruction by the T lymphocytes of the patient’s immune system, have developed an adaptive mechanism in which the ligand expressed on their surface binds to the PD-1 receptor on the cells of the immune system and in this way, mimicking physiological mechanisms, inhibits the proliferation of T lymphocytes and promotes their depletion—it silences the immune response, which allows the tumor to escape from the host’s own mechanisms [78].